Mode
Text Size
Log in / Sign up
N/A N=54 Randomized Single-blind Treatment

A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)

Multiple Sclerosis

Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcome: Primary: Adherence — 2; 6; 10; 12 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Frequent Patient Interaction (Other); Timing Restriction (Behavioral); LoseIt! Smartphone Application (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Jun 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Adherence
2; 6; 10; 12
SECONDARY
Body Mass Index (BMI)
-0.83; -1.03; 0.04; -0.22
SECONDARY
Weight Change
-2.15; -2.85; 0.12; -0.52
SECONDARY
Weight Change Among Adherent Participants
-4.97; -0.22
SECONDARY
Functional Assessment in MS Score
-3.96; 5.73; 5.42; 2.17
SECONDARY
Fatigue
-3.38; -2.07; -0.58; 1.18
SECONDARY
Sleep Quality
-1.33; -0.75; -1.50; -0.73
SECONDARY
Self-esteem
0.39; -1.00; -1.00; 1.41

Summary

This is a pragmatic, single-blinded randomized trial of improving adherence to dietary interventions in patients with MS who are receiving monthly natalizumab infusions.

Eligibility Criteria

Inclusion Criteria

  • Body Mass Index (BMI) ≥ 25 kg/m^2 for calorie restriction study
  • BMI < 25 kg/m^2, or ≥ 25 kg/m^2 if participant was unwilling to enroll in calorie restriction study
  • Smartphone with the ability to download and use the LoseIt! application (calorie restriction only)
  • Smartphone with the ability to take and store photos (calorie timing only)

Exclusion Criteria

  • History of diabetes requiring medication
  • Currently pregnant or breastfeeding
  • History of an eating disorder
  • Currently taking warfarin
  • History of major surgery within past 3 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02846558). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search